Europe Precision Oncology Market Size & Outlook, 2025-2030
Europe Precision Oncology Market, 2018-2030 (US$M)
Global Market
Related Markets
Europe precision oncology market highlights
- The Europe precision oncology market generated a revenue of USD 30,787.3 million in 2024.
- The market is expected to grow at a CAGR of 9.4% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 30,787.3 million |
| Market revenue in 2030 | USD 52,610.0 million |
| Growth rate | 9.4% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.6% of the global precision oncology market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 50,287.5 million by 2030.
The precision oncology market in Europe is likely to emerge as a lucrative region due to the growing focus on innovative therapies for rare cancers through strategic collaborations and advancements in radioligand treatments. For instance, in September 2024, Sanofi announced a licensing agreement with RadioMedix and Orano Med highlighting the development of AlphaMedix (212Pb-DOTAMTATE), a targeted alpha therapy for somatostatin receptor-expressing neuroendocrine tumors.
This next-generation radioligand medicine leverages lead-212 to deliver precise, targeted cancer treatment, addressing the unmet needs of patients with rare and difficult-to-treat cancers. Such initiatives are advancing precision medicine in Europe, driving growth through innovative solutions tailored to specific cancer subtypes.
No credit card required*
Publish Date: Jan 22, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Exact Sciences Corp | View profile | 6,600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | www.exactsciences.com |
| Invitae Corp | View profile | 1,700 | 1400 16th Street, San Francisco, CA, United States, 94103 | www.invitae.com |
| Rain Oncology | View profile | 101-250 | Newark, California, United States, North America | www.rainoncology.com |
| Strata Oncology | View profile | 51-100 | Ann Arbor, Michigan, United States, North America | www.strataoncology.com/ |
| Xilis | View profile | 51-100 | Durham, North Carolina, United States, North America | www.xilis.net |
| Variantyx | View profile | 101-250 | Framingham, Massachusetts, United States, North America | www.variantyx.com |
| BioServe | View profile | 51-100 | Beltsville, Maryland, United States, North America | bioserve.com |
Europe Precision Oncology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Oncology Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 77.83% in 2024.
Horizon Databook has segmented the Europe precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in Europe is likely to emerge as a lucrative region due to the growing focus on innovative therapies for rare cancers through strategic collaborations and advancements in radioligand treatments. For instance, in September 2024, Sanofi announced a licensing agreement with RadioMedix and Orano Med highlighting the development of AlphaMedix (212Pb-DOTAMTATE), a targeted alpha therapy for somatostatin receptor-expressing neuroendocrine tumors.
This next-generation radioligand medicine leverages lead-212 to deliver precise, targeted cancer treatment, addressing the unmet needs of patients with rare and difficult-to-treat cancers. Such initiatives are advancing precision medicine in Europe, driving growth through innovative solutions tailored to specific cancer subtypes.
- Europe Precision Oncology Market Product Outlook (Revenue, USD Million , 2018-2030)
- Diagnostics
- Therapeutics
- Europe Precision Oncology Market Cancer Outlook (Revenue, USD Million , 2018-2030)
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Others
- Europe Precision Oncology Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Healthcare Data Companies
Reasons to subscribe to Precision Oncology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Precision Oncology Market Outlook databook
- Our clientele includes a mix of Precision Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Precision Oncology Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Precision Oncology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Europe Precision Oncology Market, 2018-2030 (US$M)
Europe Product - Precision Oncology Market Statistics, 2024 - 2030 (US$M)
